Broadcast Date: 
  • Time: 

During the development, production, and quality control of protein-based biotherapeutics, it’s imperative to characterize and monitor the released N-glycan profile. Historically this has been challenging due to extensive labeling protocols and compromises in fluorescence (FLR) and mass spectrometric (MS) sensitivities of different labels. Recently the GlycoWorks™ RapiFluor-MS™ N-Glycan kit has been introduced to address these challenges. With this technology, users can complete N-glycan sample preparation, from glycoprotein to ready-to-analyze sample, in just 30 minutes. More significantly, the RapiFluor-MS improves FLR and MS sensitivities while streamlining the overall N-glycan sample throughput.

These advancements now allow, for the first time, the use of mass detection for glycan analyses during method development, process development, and quality control where access to highend mass spectrometers is limited. In this webinar we will provide case study examples of applications where the combined orthogonal
FLR and mass data, collected within a single integrated workflow, provides critical insights about the composition of a glycan profile for data-driven confidence in decisions made during late-phase protein development and QC.

Who Should Attend

  • Biochemists
  • Biopharmaceutical and therapeutic protein developers
  • Scientists developing biopharmaceutical analytical workflows
  • QC/QA scientists manufacturing therapeutic proteins
  • Protein analytical scientists interested in glycan analysis

You Will Learn

  • How a breakthrough rapid tagging technology, which offers improved fluorescence and unrivaled MS detection, simplifies and shortens the process of glycan release, labeling, and cleanup from glycoproteins.
  • How the ACQUITY QDa® mass detector has been designed for use by chromatographers, how suitable it is for monitoring glycans, and how this technology can be easily and seamlessly deployed in compliant-ready environments that use Empower Software.
  • Why mass detection revolutionizes the decision-making process during routine monitoring of released N-glycans profiles when using RapiFluor-MS.
  • The important role that user-friendly mass detection technology can play in glycan applications as well as for peptides, excipients, and oligonucleotides.

Produced with support from:


Stephan M. Koza, Ph.D.
Principal, Applications Chemist,
Waters Corporation

Sean M. McCarthy, Ph.D.
Senior Manager,
Waters Corporation